AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE
Retrieved on:
Wednesday, July 29, 2020
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.
Key Points:
- Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.
- Amryt comprises a strong and growing portfolio of commercial and development assets.
- FILSUVEZ has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the FDA.
- Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.